info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
7
Aug
CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
5
Aug
CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
31
Jul
CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
18
Jun
CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
17
Jun
CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference
11
Jun
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
20
May
CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019
8
May
CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update
8
May
CymaBay Therapeutics Announces Multiple Presentations at DDW 2019
30
Apr
CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8
<< Previous
1
2
3
4
Next >>
Show All
Scroll
